Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Is GSK plc GSK an Undervalued Defensive Stock for 2025?

January 25, 2025
GSK plc (NYSE: GSK) has been gaining attention as a potential undervalued defensive stock for investors looking towards 2025. With its strong portfolio of pharmaceuticals and vaccines, the company has been a key player in the healthcare industry for many years.

Despite facing challenges in the past, GSK has been working on reshaping its business and focusing on therapeutics that have the potential to generate strong revenues. The company's recent collaboration with Vir Biotechnology on the development of COVID-19 treatments has also brought positive attention.

GSK's diverse product lineup, which includes popular brands such as Advair and Trelegy, provides stability and consistent cash flow. The company's robust pipeline of drugs in development further adds to its growth potential.

Furthermore, GSK's efforts in expanding its presence in emerging markets, particularly in Asia, have been promising. As these regions continue to develop and invest in healthcare, GSK stands to benefit from increased demand for its products.

While uncertainties in the pharmaceutical industry remain, GSK's solid financial position and defensive characteristics position it well for long-term growth. Its attractive dividend yield also adds to the appeal for income-seeking investors.

Considering GSK's potential for growth and its undervalued status, it might be worth exploring investment opportunities in this company. However, as with any investment decision, it is recommended to consult with professionals, such as Stocks Prognosis, who can provide expert analysis and forecasts on the movement of GSK's shares.
If you want to leave a comment, then you need Login or Register





Other data for GSK

Related data

GSKJuly 17, 2025QuantWave Successfully Predicts GSK PLC Stock Movement, Achieving 7.53% Profit  ~2 min.

QuantWave, the automated forecasting platform, has once again proven its accuracy with the successful prediction of the price movement of GSK PLC stock....


GSKJuly 17, 2025QuantWave Hits Bullseye with GSK PLC Forecast, Achieving 7.53% Profit  ~2 min.

On May 27, 2025, QuantWave, the automated forecasting platform, issued a short signal for GSK PLC with a price target of 36.07 $. The stock was trading at 39....


GSKJune 12, 2025QuantWave Achieves 14.92% Profit Target Forecast for GSK PLC  ~1 min.

QuantWave, the automated forecasting platform, successfully reached a price target forecast for GSK PLC, yielding a profit of 14.92%....


GSKJune 12, 2025QuantWave Successfully Achieves 10.55% Profit Target Forecast for GSK PLC  ~2 min.

QuantWave, the automated forecasting platform, has recently hit a milestone with its accurate prediction for the stock of GSK PLC....


GSKJune 12, 2025QuantWave Hits Bullseye with GSK PLC Forecast, Generating 9.06% Profit  ~2 min.

QuantWave, the cutting-edge automated forecasting platform, has once again demonstrated its accuracy with an impressive 9.06% profit on the stock of GSK PLC....


GSKJune 12, 2025QuantWave Forecast Hits the Mark: GSK PLC Stock Reaches Price Target with 9.53% Profit  ~2 min.

On March 21, 2025, QuantWave, the automated forecasting platform, issued a long signal for GSK PLC stock when it was trading at $38.37. Fast forward to June 12, 2025, the predicted target of $42....


GSKJune 12, 2025QuantWave Hits Price Target Forecast for GSK PLC with 7.32% Profit  ~2 min.

On March 7, 2025, QuantWave, an automated forecasting platform, successfully forecasted a price target for the stock GSK PLC. The signal indicated a long position when the stock was trading at 39.16 $....


GSKJune 12, 2025QuantWave Successfully Predicts GSK PLC Stock Price, Generating 11.84% Profit  ~1 min.

On March 4th, 2025, QuantWave, the automated forecasting platform, issued a long signal for GSK PLC stock at a price of $37.58....


GSKJune 12, 2025QuantWave Forecasts Success: GSK PLC Hits Price Target with 8.84% Profit  ~1 min.

On March 14, 2025, QuantWave, an automated forecasting platform, issued a long signal for the stock of GSK PLC at a price of 38.61 $. Fast forward to June 12, 2025, the target price of 42....


GSKJune 12, 2025QuantWave Achieves 8.81% Profit Target Forecast for GSK PLC Stock  ~1 min.

QuantWave, the automated forecasting platform, successfully reached its price target forecast for GSK PLC stock, with a profit margin of 8.81%....


LLYNovember 28, 2024Healthcare Stocks Got Crushed After the Election - Is It Time to Buy Eli Lilly?  ~2 min.

Eli Lilly and Company (LLY) shares have seen a significant dip after the recent election, along with other healthcare stocks....


REGNFebruary 3, 2025Regeneron Pharmaceuticals Inc. Receives Positive Analyst Recommendations  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) has recently received bullish recommendations from leading analysts, indicating a positive outlook for the company's future....


REGNJanuary 4, 2025Regeneron Pharmaceuticals Inc.: A Strong Investment Opportunity for Shareholders  ~1 min.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has proven to be a successful investment option for shareholders, with a decent 89% return over the last five years....


ABBVNovember 6, 2024AbbVie Inc Collaborates with EvolveImmune Therapeutics to Develop Next-Generation Cancer Biotherapeutics  ~2 min.

AbbVie Inc. (NYSE: ABBV), a global pharmaceutical company, has announced a collaboration with EvolveImmune Therapeutics to develop next-generation cancer biotherapeutics....


ABBVMarch 20, 2025AbbVie Inc. ABBV is Experiencing Global Investor Interest: A Look into the Company's Success Story  ~2 min.

AbbVie Inc., a renowned pharmaceutical company, has been making waves in the global market, attracting significant attention from investors worldwide....